Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: New perspectives for cellular therapy

Giampiero La Rocca, Melania Lo Iacono, Tiziana Gorgun, Simona Corrao, Felicia Farina, Rita Anzalone

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Rheumatoid arthritis and osteoarthritis are the main diseases that imply an inflammatory process at the joints involving the articular cartilage. Recently, mesenchymal stem cells (MSCs) derived from perinatal tissues were considered good candidates for cellular therapy of musculoskeletal and orthopaedic diseases, since they can differentiate into multiple cell types and are an easily accessible cellular source. Therefore, several protocols exist on the differentiation of mesenchymal stem cells of different origins into osteoblasts and chondrocytes. Another key feature of MSCs is their capacity to modulate the immune system responses in vitro and in vivo. This may have critical outcomes in diseases of the musculoskeletal system where an inflammatory or autoimmune process is at the basis of the main disease. In the present paper, after isolation of MSCs from Wharton's Jelly (WJ-MSCs), we performed the three standard differentiation protocols. The acquisition of the differentiated phenotype was demonstrated by the specific histological stains. As the main objective of this work, we determined the expression of immunomodulatory molecules (by immunohistochemistry and qualitative RT-PCR), both in undifferentiated cells and after differentiation. We demonstrated for the first time that immune-related molecules (as B7-H3/CD276 and HLA-E) which have been characterized in undifferentiated MSCs, are also expressed by the differentiated progeny. This strongly suggests that also after the acquisition of a mature phenotype, WJ-MSCs-derived cells may maintain their immune privilege. This evidence, which deserves much work to be confirmed in vivo and in other MSCs populations, may provide a formal proof of the good results globally achieved with WJMSCs as cellular therapy vehicle.

Original languageEnglish (US)
Pages (from-to)100-113
Number of pages14
JournalCurrent Stem Cell Research and Therapy
Volume8
Issue number1
DOIs
StatePublished - Jul 10 2013
Externally publishedYes

Fingerprint

Wharton Jelly
Mesenchymal Stromal Cells
Therapeutics
B7 Antigens
Musculoskeletal Diseases
Phenotype
Musculoskeletal System
In Vitro Techniques
Articular Cartilage
Chondrocytes
Osteoblasts
Osteoarthritis
Orthopedics
Cell Differentiation
Immune System
Rheumatoid Arthritis
Coloring Agents
Joints
Immunohistochemistry

Keywords

  • Adipogenic differentiation
  • Chondrogenic differentiation
  • Immune modulation
  • Mesenchymal stem cells
  • Osteogenic differentiation
  • Regenerative medicine
  • Tissue repair
  • Umbilical cord
  • Wharton's jelly

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro : New perspectives for cellular therapy. / La Rocca, Giampiero; Lo Iacono, Melania; Gorgun, Tiziana; Corrao, Simona; Farina, Felicia; Anzalone, Rita.

In: Current Stem Cell Research and Therapy, Vol. 8, No. 1, 10.07.2013, p. 100-113.

Research output: Contribution to journalArticle

@article{c322057f750d4e2c86fbeee2fd7bd543,
title = "Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: New perspectives for cellular therapy",
abstract = "Rheumatoid arthritis and osteoarthritis are the main diseases that imply an inflammatory process at the joints involving the articular cartilage. Recently, mesenchymal stem cells (MSCs) derived from perinatal tissues were considered good candidates for cellular therapy of musculoskeletal and orthopaedic diseases, since they can differentiate into multiple cell types and are an easily accessible cellular source. Therefore, several protocols exist on the differentiation of mesenchymal stem cells of different origins into osteoblasts and chondrocytes. Another key feature of MSCs is their capacity to modulate the immune system responses in vitro and in vivo. This may have critical outcomes in diseases of the musculoskeletal system where an inflammatory or autoimmune process is at the basis of the main disease. In the present paper, after isolation of MSCs from Wharton's Jelly (WJ-MSCs), we performed the three standard differentiation protocols. The acquisition of the differentiated phenotype was demonstrated by the specific histological stains. As the main objective of this work, we determined the expression of immunomodulatory molecules (by immunohistochemistry and qualitative RT-PCR), both in undifferentiated cells and after differentiation. We demonstrated for the first time that immune-related molecules (as B7-H3/CD276 and HLA-E) which have been characterized in undifferentiated MSCs, are also expressed by the differentiated progeny. This strongly suggests that also after the acquisition of a mature phenotype, WJ-MSCs-derived cells may maintain their immune privilege. This evidence, which deserves much work to be confirmed in vivo and in other MSCs populations, may provide a formal proof of the good results globally achieved with WJMSCs as cellular therapy vehicle.",
keywords = "Adipogenic differentiation, Chondrogenic differentiation, Immune modulation, Mesenchymal stem cells, Osteogenic differentiation, Regenerative medicine, Tissue repair, Umbilical cord, Wharton's jelly",
author = "{La Rocca}, Giampiero and {Lo Iacono}, Melania and Tiziana Gorgun and Simona Corrao and Felicia Farina and Rita Anzalone",
year = "2013",
month = "7",
day = "10",
doi = "10.2174/1574888X11308010012",
language = "English (US)",
volume = "8",
pages = "100--113",
journal = "Current Stem Cell Research and Therapy",
issn = "1574-888X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro

T2 - New perspectives for cellular therapy

AU - La Rocca, Giampiero

AU - Lo Iacono, Melania

AU - Gorgun, Tiziana

AU - Corrao, Simona

AU - Farina, Felicia

AU - Anzalone, Rita

PY - 2013/7/10

Y1 - 2013/7/10

N2 - Rheumatoid arthritis and osteoarthritis are the main diseases that imply an inflammatory process at the joints involving the articular cartilage. Recently, mesenchymal stem cells (MSCs) derived from perinatal tissues were considered good candidates for cellular therapy of musculoskeletal and orthopaedic diseases, since they can differentiate into multiple cell types and are an easily accessible cellular source. Therefore, several protocols exist on the differentiation of mesenchymal stem cells of different origins into osteoblasts and chondrocytes. Another key feature of MSCs is their capacity to modulate the immune system responses in vitro and in vivo. This may have critical outcomes in diseases of the musculoskeletal system where an inflammatory or autoimmune process is at the basis of the main disease. In the present paper, after isolation of MSCs from Wharton's Jelly (WJ-MSCs), we performed the three standard differentiation protocols. The acquisition of the differentiated phenotype was demonstrated by the specific histological stains. As the main objective of this work, we determined the expression of immunomodulatory molecules (by immunohistochemistry and qualitative RT-PCR), both in undifferentiated cells and after differentiation. We demonstrated for the first time that immune-related molecules (as B7-H3/CD276 and HLA-E) which have been characterized in undifferentiated MSCs, are also expressed by the differentiated progeny. This strongly suggests that also after the acquisition of a mature phenotype, WJ-MSCs-derived cells may maintain their immune privilege. This evidence, which deserves much work to be confirmed in vivo and in other MSCs populations, may provide a formal proof of the good results globally achieved with WJMSCs as cellular therapy vehicle.

AB - Rheumatoid arthritis and osteoarthritis are the main diseases that imply an inflammatory process at the joints involving the articular cartilage. Recently, mesenchymal stem cells (MSCs) derived from perinatal tissues were considered good candidates for cellular therapy of musculoskeletal and orthopaedic diseases, since they can differentiate into multiple cell types and are an easily accessible cellular source. Therefore, several protocols exist on the differentiation of mesenchymal stem cells of different origins into osteoblasts and chondrocytes. Another key feature of MSCs is their capacity to modulate the immune system responses in vitro and in vivo. This may have critical outcomes in diseases of the musculoskeletal system where an inflammatory or autoimmune process is at the basis of the main disease. In the present paper, after isolation of MSCs from Wharton's Jelly (WJ-MSCs), we performed the three standard differentiation protocols. The acquisition of the differentiated phenotype was demonstrated by the specific histological stains. As the main objective of this work, we determined the expression of immunomodulatory molecules (by immunohistochemistry and qualitative RT-PCR), both in undifferentiated cells and after differentiation. We demonstrated for the first time that immune-related molecules (as B7-H3/CD276 and HLA-E) which have been characterized in undifferentiated MSCs, are also expressed by the differentiated progeny. This strongly suggests that also after the acquisition of a mature phenotype, WJ-MSCs-derived cells may maintain their immune privilege. This evidence, which deserves much work to be confirmed in vivo and in other MSCs populations, may provide a formal proof of the good results globally achieved with WJMSCs as cellular therapy vehicle.

KW - Adipogenic differentiation

KW - Chondrogenic differentiation

KW - Immune modulation

KW - Mesenchymal stem cells

KW - Osteogenic differentiation

KW - Regenerative medicine

KW - Tissue repair

KW - Umbilical cord

KW - Wharton's jelly

UR - http://www.scopus.com/inward/record.url?scp=84879756236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879756236&partnerID=8YFLogxK

U2 - 10.2174/1574888X11308010012

DO - 10.2174/1574888X11308010012

M3 - Article

C2 - 23317435

AN - SCOPUS:84879756236

VL - 8

SP - 100

EP - 113

JO - Current Stem Cell Research and Therapy

JF - Current Stem Cell Research and Therapy

SN - 1574-888X

IS - 1

ER -